Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Yuliya Mikheeva, MD
Advertisement
Articles by Yuliya Mikheeva, MD
Yuliya Mikheeva, MD, PhD, discusses the design of the phase 2 ANAPLAST-NEO study
Yuliya Mikheeva, MD, discusses the phase 2 ANAPLAST-NEO study for patients with anaplastic thyroid cancer.
Advertisement
Latest Updated Articles
BRAF/MEK Combo Might Increase Survival in Patients With Anaplastic Thyroid CancerPublished: March 5th 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
